Having just filed trilaciclib in the US and beefed up its commercial operations, G1 Therapeutics Inc. has made a surprise decision not to go it alone marketing the cancer drug but has inked a co-promotion agreement with Boehringer Ingelheim International GmbH instead.
Under the terms of the three-year deal, G1 and Boehringer will collaborate on the commercialization in the US and Puerto Rico of trilaciclib, a myelosuppression therapy administered before chemotherapy, for its first potential indication in small-cell lung cancer (SCLC)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?